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1010-147 Coadministration of Ezetimibe With Simvastatin Administration-Time Dependent Effects of Aspirin on 
Blood Pressure in Untreated Hypertensive Patients 
Adrian S. DobS John R. Guyton, Dennis McClusky, Damien Ponsonnet, Lorenzo Melani, 
Alexandra Labeaut. Bo Yana. Enrico Veltri. the Ezetimibe Study Group. Johns Hopkins 
Medical Center, Baltrmore, UD. Schering-Plough Research Institute. Kenilworth. NJ 
Ramon C. Hermida, Diana E. Ayala, Carlos C&o, Jose E. Lopez, Jose R. Fernandez. 
Artemio Moron. Maria J. Dominguez. Manuel Covelo, Univ. Vlgo. Vigo, Spain, Hospital 
Clinico Universrtario, Santiago de Compostela, Spain 
Background: Previous studies on the potential influence of aspirin (ASA) on blood pres- 
pure (BP) have not taken into consideration the chronopharmacologic effects of nonste- 
roldal antiinflammatory drugs. This study investigated the effects of ASA on BP in 
untreated hypertensive patients who received ASA at different tomes of the day accordmg 
to their rest-activity cycle. 
Methods: We studied 147 p&ants wth mild hypertension (57 men), 43.0+12.1 
(mean&D) years of age, divided m 3 groups: non-pharmacological hygiemc-dietary rec- 
ommendations (HDR); the same HDR and ASA (100 mg/day) on awakening; or HDR and 
ASA before bedtime. BP and heart rate (HR) were measured every 20 minutes during 
the day (07:OO to 23:00 hours) and every 30 minutes at night for 48 consecutive hours 
before and after 3 months of intervention. The clrcadlan pattern of BP in each group was 
established by population multlple-component analysis. 
Results: After 3 months of non-pharmacological Intervention, there was a small and non- 
significant reduction of BP (1.1 mm Hg for systolic BP, 1.0 mm Hg for diastolic BP; 
P>O.341). There was no effect of ASA on BP when given on awakening (P=O.229). A BP 
reduction was. however, highly significant when ASA was given before bedtime 
(decrease of 6 and 4 mm Hg m systolic and diastolic BP, respectwely; P<O.OOl). There 
was no significant change in HR in any group. 
Conclusion: Results Indicate a statistvxlly significant admmlstration-time dependent 
effect of low-dose aspirin on blood pressure in untreated patients with mild hypertension. 
These results could be related to the circadian-time dependent effects of ASA on b-adr- 
energic receptors and/or the previously demonstrated time-dependent reduction by ASA 
of the circulating levels of angiotensln II, an issue that deserves further investigation In 
any trral of ASA effects, lnquirles about the time when subjects took the drug are indi- 
cated and may account for discrepancies in the literature. Moreover, the mfluence of ASA 
on BP demonstrated here indicates the need to Identify and control for ASA effects in 
patients usmg this drug before or dwng their palticipation in antihypertensive medication 
trials. 
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1010-146 Early Fluvastatin Treatment Reduces the Long-Term 
Incidence of Major Adverse Cardiovascular Events 
Following Successful First Percutaneous Coronary 
Intervention With or Without the Use of Stent: The 
Lescolfi Intervention Prevention Study 
Francesco Saia, Angelo Branzi, G. Hendrickx, Harry Suryapranata, A. Cequier, 
Giuseppe Specchia, N. Delarche, Dick Goedhart, Plm de Feyter, Patrick W. Serruys. 
Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands, University of Bologna, 
Bologna, Italy 
Background: The Lescol@ lnterventton Prevention Study (LIPS), an international dou- 
ble-blind placebo-controlled clinlcal trial, has shown that early fluvastatin treatment signif- 
icantly reduces the risk of major adverse cardwascular events (MACE) compared with 
placebo in patients with average cholesterol levels after their first successful percutane- 
ous coronary intervention (PCI). The use of stems during PCI is associated with lower 
early and late adverse cardiac event rates. This study assessed the effects of fluvastatin 
on MACE in patients treated with either stent or balloon angloplasty. 
Methods: In LIPS, 1,677 patwants wrth baseline total cholesterol levels 135-270 mg/dL, 
and fasting triglycertde levels ~400 mg/dL were included. Following successful comple- 
tion of their first PCI, they were randomized to receive fluvastatin 40 mg twice daily (844) 
or placebo (833) at hospital discharge. Follow-up was 3-4 years. 1,055 patients had at 
least one stent implanted (fluvastatin, n=540; placebo, n=515), and 582 patients were 
treated wth conventional balloon angioplasty (fluvastatin. n=287; placebo, n=295). Pri- 
mary endpoint was the survival time free of MACE, defmed as the composite of cardiac 
death, myocardlal infarction, and reinterventlons (PTCA or CABG). 
ResuI1s: In patients treated with balloon angioplasty, fluvastatin significantly reduced the 
rrsk of MACE by 28% (RR, 0.72; 95% Cl, 0.52-1.00; p=O.O48) compared with placebo. 
Among patients treated with stents, there was a clear trend towards risk reduction with 
fluvastatin (RR, 0.80; 95% Cl, 0.62-i .04; p=O.O96). In a prespecrfied analysis excluding 
reinterventions due to target lesson revascularization in the first 6 months of follow-up, the 
benefit of fluvastatin was greater and statistically significant in both groups compared 
with placebo a 43% risk reductmn in the balloon only group (RR, 0.57, 95% Cl, 0.38. 
0.84; p=O.O04), and a 29% risk reduction in the stents group (RR, 0.57; 95% Cl, 0.54. 
0.94; p=O.O2). No differences were observed in lipld profiles between the balloon and the 
stem patrants 
Conclusion: Early fluvastatin treatment significantly reduces the risk of MACE I” 
patients after PCI, with or wlthout stentmg. 
Background: This study assessed the efficacy and safety of ezetimibe (EZE), a novel 
cholesterol absorption Inhibitor, coadmmistered with simvastatin (SIM) in patients with 
heterozygous familial hypercholesterolemia (heFH), coronary heart disease (CHD), or 
multiple cardiovascular risk factors. 
Methods Following dietary stabilization. a 6.10.week drug washout, and open-label SIM 
20 mg/d run-in, 100 patlents with baseline LDL-C 2130 mg/dL and TG 450 mg/dL wh!le 
on SIM 20 mg were randomized to EZE 10 mg or additional double-blind SIM 20 mg. SIM 
dose was doubled after 4 or 9 weeks if LDL-C was still >lOO mg/dL (maximum of 80 mg 
with SIM alone and 40 mg with EZE+SIM). The primary endpoint was % LDL-C reduction 
from baseline for EZE+SIM 20 mg vs. SIM 40 mg alone at Week 4 The key secondary 
endpoint was the proportion of patients achieving LDL-C<lOO mg/dL at Week 14. 
Results Of 100 randomized patients, 22% had heFH, 42% had CHD and 40% had 2 or 
more cardwascular risk factors. EZE+SIM 20 mg (n=66) significantly reduced LDL-C vs. 
SIM 40 mg (n=34) alone; 24.5% vs. 11 .l%. p<O.Ol (table). At Week 14, 27% of the coad- 
ministration group vs. 3% of the SIM group achieved target LDL-C (pcO.01). EZE+SIM 
was well tolerated with a safety profile similar to SIM alone. 
Conclusion Adding EZE to ongoing SIM provides significantly greater LDL-C reduction 
than doubling the SIM dose alone. The coadministration of EZE+SIM offers a highly effi- 
cacious and well tolerated new treatment approach to patients with hypercholesterlemia. 




Baseline LDL-C: mean Week 4 LDL-C: mean Mean (SEM) % 
(SEM) mg/dL (SEM) mg/dL change 
167 (8) 148 (6) -11.1 (2.0) 
EZE+SIM 171 (6) 128 (5) -24.5 (1.5)’ 
20mg (n=66) 
‘p<O.Ol, EZE+SIM versus SIM alone 
1010-148 Patients After Acute Myocardial Infarction Have for a 
Prolonged Period Increased Thermal Heterogeneity in 
Culprit Atherosclerotic Lesions: Additional Effect of 
Statins on Plaque Stabilization 
Konstantinos Toutouzas, Sophia Vaina, Eleftherios Tslamis. Dimos Panagiotakos, 
loannis Mitropoulos, Costas Tsioufis, loannis Kallikazaros, Christos Pitsavos, Pavlos 
Toutouzas,Chrlstodoulos Stefanadis, Hippokration Hospital, Athens. Greece 
Background: It has been observed that patients with acute myocardial infarction (Ml) 
have increased temperature of the culprit atherosclerotic lesion. The aim of this study 
was to investigate whether this finding is maintained after acute myocardial infarction. 
Methods: In the study we enrolled 31 patients (pts): 12 (mean age: 52.3+12.3 yrs) with a 
Ml 2-4 months before the measurements and 19 pts (mean age: 59.8+11.4 yrs) with 
chronic stable angina (CSA). All pts &denvent coronary angrography and temperature 
measurements of the culprit lesion. Pts with Ml had one vessel disease. We measured 
temperature difference (TD) between the atherosclerotic plaque and the proximal vessel 
wall (background temperature) with a thermography catheter (Medispes, ZWG, Switzer- 
land). At the distal end of thts catheter a thermistor probe is attached and the measure- 
ments are displayed on real-time on the screen of a computer. 
Results: The baseline clinical characteristics were similar between the 2 groups. Pts 
with previous Ml did not suffer from post-MI angina. Pts with CSA were stabilized by 
usual medication at least for the last 2 months. None of pts with CSA had previous Ml. 
The mean value of TD was higher in pts with previous Ml than in pts with CSA 
(0.59*0.6l”C versus 0.20+0.18”C, p=O.OZ). Pts with previous MI (n=6) receiving statins 
had only a trend towards higher plaque temperature compared to treated pts with CSA 
(n=9) (0.41+0.35”C versus 0.19+0.2O”C. p=O.ll). However, pts with previous Ml not 
treated with statins (n=6) had significantly higher TD compared to untreated pts with CSA 
(n=lO) (0.76*0.7O”C “er~us 0.27~O.Ol”C. pcO.01). 
Conclusions: In patients with acute myocardial infarctlon Increased plaque temperature 
is observed for a prolonged period. Thus, the inflammatory process may be maintamed 
even after plaque rupture. Prolonged treatment with therapeutic agents, such as statins, 
for plaque stabilization may be required in pts with previous Ml. 
1010-149 Effects of Switching to Rosuvastatin From Atorvastatin 
or Other Statins on Achievement of International Low- 
Density Lipoprotein Cholesterol Goals: MERCURY I 
Trial 
Herbert Schuster, on behalf of the MERCURY I study group, INFOGEN Medlzinlsche 
Genetik GmbH, Berlin, Germany 
Background: Achievement of low-density lipoprotein cholesterol (LDL-C) goals is an 
important aim in clinical practae. This multinational trial (4522lUOOEl) assessed the effl- 
cacy of rosuvastatin to bring additional patients to LDL-C goals and modify LDL-C and 
other lipid measures vs atorvastatin and other statins in hypercholesterolemic patients 
with atherosclerosis or coronary heart disease or type 2 diabetes. 
Methods: After a 6-wk dietary lead-in period, 3161 adults were randomized to open-label 
rosuvastatin IOmg (RIO), atorvastatln 1Omg (AlO), atorvastatin 20mg (AZO). simvastatin 
20mg, or pravastatin 40mg for 8 wks. Patients then remained on these treatments or 
switched (switch groups) as follows for 8 wks: l/2 from AlO, simvastatrn 20mg and prav- 
as&tin 40mg to RlO; l/3 each from A20 to RlO and R20. Treatment comparisons were 
made at wks 8 and 16 using logistic regression analyses for percentage of patients 
